AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8139135
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant human erythropoietin (rHuEPO) at doses of 3,000 and 6,000 IU, administered once per week for 8 weeks.
Trial: 2761587
Drug: Ticlopidine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (500 mg daily)
Trial: 20868461
Drug: Family‐Focused Treatment‐Health
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family‐Focused Treatment‐Health Promoting Intervention (FFT‐HPI)
Trial: 17219034
Drug: Ropinirole at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole at 15 mg per day
Trial: 17219034
Drug: Pramipexole at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole at 2.1 mg per day
Trial: 11106918
Drug: octreotide LAR
RxNorm normalized name: octreotide LAR 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: octreotide LAR 20 mg once monthly for three months
Trial: 8842608
Drug: Hyperglycemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemia (blood glucose 15.7 +/‐ 0.48 mmol/l)
Trial: 8842608
Drug: Euglycemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycemia (blood glucose 5.1 +/‐ 0.04 mmol/l)
Trial: 31520149
Drug: Psycho-educational group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psycho-educational group therapy module (STEM) with 8 sessions plus 3 sessions on stigma coping and empowerment
Trial: 31520149
Drug: Standard psychoeducational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard psychoeducational group therapy extended to 11 sessions plus 1 booster session
Trial: 31520149
Drug: Psycho-educational group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psycho-educational group therapy module (STEM)
Trial: 31520149
Drug: Standard psychoeducational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard psychoeducational group therapy
Trial: 27706464
Drug: High-flow conditioned
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow conditioned oxygen therapy
Trial: 21178076
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (400 mg daily)
Trial: 580217
Drug: 1‐(m‐methoxyphenyl)‐2‐(dimethylaminomethyl)‐cyclohexan‐1‐ol (tramadol;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1‐(m‐methoxyphenyl)‐2‐(dimethylaminomethyl)‐cyclohexan‐1‐ol (tramadol; Tramal) 100 mg i.m.
Trial: 19955857
Drug: LAT patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAT patients without warfarin
Trial: 9383499
Drug: Granisetron (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (1 mg tablets/2 mg oral dose)
Trial: 8042069
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course treatment
Trial: 28148473
Drug: Conventional preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional preparation methods
Trial: 23338056
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block with 0.25% levobupivacaine 0.5 ml kg(‐1)
Trial: 23338056
Drug: Wound infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wound infiltration with 0.2 ml kg(‐1) 0.25% levobupivacaine
Trial: 10714908
Drug: E2-DSG (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2-DSG (1.5 mg E2 for 24 days with 0.15 mg DSG for the last 12 days followed by a placebo tablet for 4 days)
Trial: 10714908
Drug: E2V-MPA (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2V-MPA (2 mg E2V for 21 days with 10 mg MPA for the last 10 days)
Trial: 10350027
Drug: Haloperidol 4
RxNorm normalized name: haloperidol 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 4 mg
Trial: 9361328
Drug: Haloperidol 6
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol 6 mg
Trial: 2942494
Drug: Lorazepam 2.5
RxNorm normalized name: lorazepam 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 2.5 mg
Trial: 24883319
Drug: Ropivacaine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine + Tramadol (50 mg)
Trial: 24883319
Drug: Ropivacaine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine + Ketamine (50 mg)
Trial: 20071289
Drug: CIPRO XR
RxNorm normalized name: Cipro XR
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CIPRO XR 1000 mg once daily
Trial: 20071289
Drug: CIPRO IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIPRO IR 500 mg twice daily
Trial: 16459272
Drug: Morphine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.1 mg/kg IV over 2 min) + Naloxone (0.1 ng/kg)
Trial: 18694635
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 300 mg/day WS 5570
Trial: 11345689
Drug: Salicis cortex
RxNorm normalized name: Salicis cortex
DrugBank: Willow bark (DB14691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salicis cortex extract with 240 mg salicin/day
Trial: 11345689
Drug: Acetylsalicylate 100
RxNorm normalized name: Acetylsalicylate
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylate 100 mg/day
Trial: 8025207
Drug: Glipizide plus
RxNorm normalized name: Glipizide
DrugBank: Glipizide (DB01067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glipizide plus intensive insulin treatment (Group B)
Trial: 10390663
Drug: Midazolam (5-7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (5-7.5 mg)
Trial: 3631495
Drug: Meperidine (50-75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (50-75 mg) and Promethazine (25-50 mg)
Trial: 31802733
Drug: Combined arms
RxNorm normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined arms of villages that received four rounds of treatment
Trial: 31802733
Drug: School-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based treatment (SBT) for first-year primary students and adults
Trial: 31684847
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) under level 1A evidence
Trial: 31684847
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) under level 2B evidence
Trial: 26720025
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus triptorelin (LHRHa group)
Trial: 17253878
Drug: Antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drugs (AEDs) with serotonergic properties (e.g., carbamazepine, oxcarbazepine, valproate, lamotrigine)
Trial: 17253878
Drug: Other AEDs
RxNorm normalized name: Bisphenol A diglycidyl ether
DrugBank: Bisphenol A diglycidyl ether (DB14083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other AEDs (e.g., topiramate, tiagabine, vigabatrin, levetiracetam, zonisamide)
Trial: 11573114
Drug: Sulphadoxine/Pyrimethamine (1500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphadoxine/Pyrimethamine (1500mg sulphadoxine and 75mg pyrimethamine as a single dose)
Trial: 11573114
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of Sulphadoxine/Pyrimethamine and Doxycycline
Trial: 30352668
Drug: Integrated Dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated Dual Diagnosis Treatment (IDDT)
Trial: 26025097
Drug: Intravitreal Aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal Aflibercept Injection (IAI) 2 mg every 4 weeks (2q4)
Trial: 19055281
Drug: Warming needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warming needle therapy
Trial: 14739418
Drug: Aphasia therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aphasia therapy
Trial: 8273399
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose betamethasone (8 mg/2 days)
Trial: 3034062
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (25, 50, 100, or 200 micrograms/day)
Trial: 3034062
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (50 micrograms patch)
Trial: 3034062
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (0.625 mg and 1.25 mg)
Trial: 24750838
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg/(m(2)·d), Qd) for 6 months
Trial: 23803270
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) for 20 minutes
Trial: 16550737
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg) from Laboratórios Cristália Ltd.
Trial: 16550737
Drug: Cozaar (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cozaar (50 mg) from Merck Sharp & Dohme Farmacêutica Ltd.
Trial: 12093324
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 to 200 mg/day)
Trial: 10819825
Drug: 3‐day diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐day diet containing at least 150 g carbohydrate per day
Trial: 1363488
Drug: Low-dose fentanyl
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fentanyl (2 micrograms/kg) and vecuronium (120 micrograms/kg)
Trial: 1363488
Drug: Propofol (induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (induction agent)
Trial: 6585733
Drug: 3-mg prostaglandin
RxNorm normalized name: PROSTAGLANDINS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-mg prostaglandin E2 (PGE2) vaginal suppository
Trial: 31733777
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment combined with core muscle strengthening exercises (Experimental Group)
Trial: 31733777
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment alone (Control Group)
Trial: 12381038
Drug: Imaginal exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imaginal exposure therapy (IET)
Trial: 29807806
Drug: Pill counts
RxNorm normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pill counts
Trial: 22459241
Drug: Polyester suture
RxNorm normalized name: polyester-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyester suture augmentation
Trial: 15995005
Drug: Vancomycin-heparin lock
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin-heparin lock solution (25 microg/mL)
Trial: 7653816
Drug: Group II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II: no spinal injection
Trial: 2015735
Drug: Triazolam, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam, 0.5 mg
Trial: 1100300
Drug: Secobarbital, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secobarbital, 100 mg
Trial: 24282870
Drug: Oral-B Triumph
RxNorm normalized name: Triumph
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B Triumph with SmartGuide (oscillating-rotating brush)
Trial: 11464183
Drug: Docosanol 10%
RxNorm normalized name: DOCOSANOL 10% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docosanol 10% cream
Trial: 9605367
Drug: Morphine 10
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 10 mg intramuscularly
Trial: 7999289
Drug: Oral-B Advantage
RxNorm normalized name: Advantage Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B Advantage Plaque Remover
Trial: 31383564
Drug: Patient Therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient Therapeutic Education (PTE) combined with spa therapy
Trial: 24196463
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration analgesia with 0.2% ropivacaine, ketorolac, and adrenaline followed by continuous infusion of 0.2% ropivacaine at 5 mL/hr
Trial: 24196463
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration analgesia with 0.2% ropivacaine, ketorolac, and adrenaline followed by continuous infusion of saline solution at 5 mL/hr
Trial: 24196463
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration with saline solution followed by continuous infusion of saline solution at 5 mL/hr
Trial: 19589264
Drug: Mitiglinide 10-20
RxNorm normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mitiglinide 10-20 mg three times daily
Trial: 19589264
Drug: Nateglinide 120
RxNorm normalized name: nateglinide 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide 120 mg three times daily
Trial: 11755327
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (5 mg)
Trial: 11755327
Drug: Epidural S(+)‐ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural S(+)‐ketamine (0.1 mg/kg)
Trial: 11755327
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (epidural saline and transdermal placebo)
Trial: 1506656
Drug: Ketanserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (10 mg)
Trial: 16417534
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) 1000 mg twice daily
Trial: 11561046
Drug: High frequency
RxNorm normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL SOLUTION [enMotion Foam High Frequency Use]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High frequency repetitive transcranial magnetic stimulation (HF‐rTMS) applied to the left dorsolateral prefrontal area in daily sessions for 10 consecutive working days.
Trial: 8162718
Drug: Verapamil, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil, 40 mg every 4 h
Trial: 2832763
Drug: Radiation plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation plus iv chemotherapy (5-fluorouracil)
Trial: 2832763
Drug: Radiation plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation plus intra-arterial chemotherapy (5-fluorouracil)
Trial: 18498540
Drug: Rectal challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal challenge with cow's milk protein (CM)
Trial: 9383177
Drug: Hypertonic NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic NaCl solution (100 mmol NaCl in 50 ml) administered to untreated hypertensives
Trial: 9383177
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (single drug or combination) for 1 month
Trial: 9383177
Drug: Clonidine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.3 mg in 100 ml)
Trial: 9023787
Drug: Imipramine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (200 mg/day)
Trial: 3318432
Drug: Nabumetone 1,000
RxNorm normalized name: nabumetone 1,000 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone 1,000 mg once daily at bedtime
Trial: 21725257
Drug: Novel Baha
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel Baha implant system
Trial: 21725257
Drug: Previous-generation implant
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous-generation implant system
Trial: 17659605
Drug: Budesonide 200
RxNorm normalized name: budesonide 200 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 200 microg twice daily
Trial: 10510140
Drug: Budesonide 800
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 800 microg twice daily
Trial: 9129752
Drug: Daily oxymetazoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oxymetazoline (b.i.d. 150 microliters per nostril)
Trial: 9129752
Drug: Daily vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vehicle (b.i.d. 150 microliters per nostril)
Trial: 3503965
Drug: Amoxicillin clavulanate
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin clavulanate + antihistaminic + nose drops therapy
Trial: 20619837
Drug: Fenofibrate (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (160 mg)
Trial: 12785672
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Qualitative and Quantitative feedback
Trial: 2520406
Drug: Guanethidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanethidine (20 mg in 50 ml 0.5% lidocaine)
Trial: 2520406
Drug: Reserpine (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reserpine (1.25 mg in 50 ml 0.5% lidocaine)
Trial: 2520406
Drug: Control (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (50 ml 0.5% lidocaine)
Trial: 28275958
Drug: Alogliptin 25
RxNorm normalized name: alogliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 25 mg once daily
Trial: 20955637
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of mitomycin C after surgical shave excision
Trial: 16705054
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion at low dose (LD, 0.05 mUxmin(‐1)x100 ml(‐1))
Trial: 16705054
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion at intermediate dose (ID, 0.15 mUxmin(‐1)x100 ml(‐1))
Trial: 16705054
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion at high dose (HD, 0.30 mUxmin(‐1)x100 ml(‐1))
Trial: 14744846
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (41% fat, 14% protein, 45% carbohydrates, and 7 g of fiber per 1000 kcal)
Trial: 8505833
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg in adults, 0.1 mg/kg in children) with unweighted tube
Trial: 3710499
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of activated charcoal
Trial: 16098233
Drug: Anti-HLA-DP antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-HLA-DP antibody
Trial: 11941551
Drug: Atovaquone plus
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atovaquone plus pyrimethamine (1500 mg orally twice daily + 75 mg per day after a 200‐mg loading dose)
Trial: 11941551
Drug: Atovaquone plus
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atovaquone plus sulfadiazine (1500 mg orally twice daily + 1500 mg 4 times daily)
Trial: 9861117
Drug: Extradural 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural 0.25% bupivacaine 4‐7 ml h‐1 and morphine 0.16‐0.28 ml h‐1
Trial: 9861117
Drug: Extradural saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural saline and conventional analgesics
Trial: 7611794
Drug: Cyclosporine 3
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine 3 mg/kg per day
Trial: 29023179
Drug: Autologous PRP
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous PRP treatment
Trial: 29023179
Drug: Basal group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal group (no treatment)
Trial: 26502012
Drug: Long-term daily
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term daily azithromycin therapy
Trial: 26066644
Drug: Olmesartan +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan + Calcium Channel Blocker (CCB)
Trial: 26066644
Drug: Olmesartan +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan + Diuretic